Dataset Information


Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector.

ABSTRACT: A tumor-selective non-lytic retroviral replicating vector (RRV), Toca 511, and an extended-release formulation of 5-fluorocytosine (5-FC), Toca FC, are currently being evaluated in clinical trials in patients with recurrent high-grade glioma (NCT01156584, NCT01470794 and NCT01985256). Tumor-selective propagation of this RRV enables highly efficient transduction of glioma cells with cytosine deaminase (CD), which serves as a prodrug activator for conversion of the anti-fungal prodrug 5-FC to the anti-cancer drug 5-fluorouracil (5-FU) directly within the infected cells. We investigated whether, in addition to its direct cytotoxic effects, 5-FU generated intracellularly by RRV-mediated CD/5-FC prodrug activator gene therapy could also act as a radiosensitizing agent. Efficient transduction by RRV and expression of CD were confirmed in the highly aggressive, radioresistant human glioblastoma cell line U87EGFRvIII and its parental cell line U87MG (U87). RRV-transduced cells showed significant radiosensitization even after transient exposure to 5-FC. This was confirmed both in vitro by a clonogenic colony survival assay and in vivo by bioluminescence imaging analysis. These results provide a convincing rationale for development of tumor-targeted radiosensitization strategies utilizing the tumor-selective replicative capability of RRV, and incorporation of radiation therapy into future clinical trials evaluating Toca 511 and Toca FC in brain tumor patients.

SUBMITTER: Takahashi M 

PROVIDER: S-EPMC4246057 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC4218156 | BioStudies
2012-01-01 | S-EPMC3437576 | BioStudies
2017-01-01 | S-EPMC5692653 | BioStudies
2015-01-01 | S-EPMC4326030 | BioStudies
2017-01-01 | S-EPMC5570153 | BioStudies
2016-01-01 | S-EPMC6707068 | BioStudies
2012-01-01 | S-EPMC3266384 | BioStudies
2018-01-01 | S-EPMC5751967 | BioStudies
1000-01-01 | S-EPMC5035524 | BioStudies
2017-01-01 | S-EPMC5574670 | BioStudies